Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:
“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.
Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.
If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.
600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.
This is especially important in ITP, where many patients still have limited durable responses to existing therapies.
By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”
Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 2, 2026, 12:22James P. Crowley: A New Adult Progenitor with Erythro-Myeloid Potential
-
Nov 2, 2026, 12:17Mokhtar Tazik: Plasma Self-Sufficiency and Sustainable Access
-
Nov 2, 2026, 12:09Alejandro González Veliz: Does More Calcium Mean More Stability
-
Nov 2, 2026, 12:05Zeev Dvashi: Advancing Synthetic Blood Technologies for Battlefield Medicine
-
Nov 2, 2026, 11:56Rob Maloney: Strengthening Patient Advocacy in Bleeding Disorders
-
Nov 2, 2026, 11:46William McKeown: Advancing Gene and Cell Therapies for Inherited Bleeding Disorders
-
Nov 2, 2026, 11:41Anawat Ratchatorn: Identifying Stroke Mimics in the Emergency Department
-
Nov 2, 2026, 11:29Shruti Gadgil: AI-Powered Smartphone Screening for Anemia Severity in Rural India
-
Nov 2, 2026, 10:41Paulus Kirchhof: Smoking or Vaping – Nicotine Still Affects Vascular Health